Myeloma Paper of the Day, July 28th, suggested by Robert Orlowski
Robert Orlowski shared on X:
“Myeloma Paper of the Day: Anti-BCMA/GPRC5D bispecific CAR-T cells show excellent activity in Phase I study of relapsed/refractory myeloma patients. Data weaknesses include early population (median 3 prior lines) and no prior BCMA or GPRC5D therapies.”
Source: Robert Orlowski/X
Authors: Dian Zhou, Qian Sun, Jieyun Xia, Weiying Gu, Jun Qian, Wanchuan Zhuang, Zhiling Yan, Hai Cheng, Wei Chen, Feng Zhu, Kunming Qi, Depeng Li, Wei Sang, Lili Zhu, Sha Ma, Hujun Li, Huanxin Zhang, Tingting Qiu, Dongmei Yan, Yanlei Zhang, Shuixiu Peng, Alex H. Chang, Kailin Xu, and Zhenyu Li
Other posts featuring Robert Orlowski on OncoDaily.
Robert Orlowski holds multiple positions at The University of Texas MD Anderson Cancer Center, including Chairman, Ad Interim Director of Myeloma, and Professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics within the Division of Cancer Medicine.
Additionally, he chairs the SWOG Barlogie/Salmon Myeloma Committee, which is part of the National Clinical Trials Network and is dedicated to advancing new therapies and understanding the biology of myeloma.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023